Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 30, 2017
Grant Date -
Mar 10, 2016
app pub date -
Mar 19, 2013
filing date -
Mar 19, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully